Norwegian version of this page

Pancreatic pathology

Pancreatic cancer is the fourth most common cause of cancer-related death in the Western world.

About the group

Mechanisms that underlie treatment resistance, such as tumour heterogeneity, tumour-stroma interactions, and metabolic rewiring are investigated on human tumour tissues and in primary human cell cultures.

The research group is part of the Norwegian Cancer Society´s National Group of Expertise on Pancreatic Cancer.


  • Morphological (intra-)tumour heterogeneity and its correlation with structural and functional diversity in pancreatic cancer.
    Funded by The Norwegian Cancer Society.
  • Characterisation of residual cancer following neoadjuvant therapy for pancreatic cancer.
    Funded by Helse Sør-Øst.
  • Ex vivo culturing of precision-cut human pancreatic cancer slices.
  • Metabolic rewiring and chemoresistance in pancreatic cancer.
    Funded by Helse Sør-Øst, Family Blix Endowment, and Fondsstiftelsen at Oslo University Hospital.
  • Implementation of imaging mass cytometry and automated whole-slideanalyses of colorectal and pancreatic cancer.
    Funded by Fondsstiftelsen at Oslo University Hospital.


Read also about our collaborative work on pancreatic cancer

Published June 12, 2020 2:43 PM - Last modified June 12, 2020 2:46 PM



Detailed list of participants